Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-Dose (MTX)-Based Chemo-Immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma.

Next Previous
Trial Profile

A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-Dose (MTX)-Based Chemo-Immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 02 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motexafin gadolinium (Primary) ; Cytarabine; Methotrexate; Procarbazine; Rituximab; Vincristine
  • Indications CNS cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 08 Apr 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment, according to ClinicalTrials.gov.
  • 20 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 20 May 2010 Planned end date changed from 1 Aug 2011 to 1 May 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top